Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sasanlimab (PF-06801591) Phase 1 in Advanced Solid Tumors
NCT02573259Phase 1Completed
- Sponsor
- Pfizer
- Start
- Feb 2016
- Primary completion
- Nov 2020
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 1, open-label trial of sasanlimab in melanoma, squamous cell carcinoma of the head and neck (HNSCC), ovarian cancer and 4 more (5 arms), sponsored by Pfizer. Primary endpoints: Percentage of Participants With Dose-Limiting Toxicities, Number of Participants With All-Causality Treatment-Emergent Adverse Events and 2 more. Started Feb 2016; status: completed.
02
Drugs
sasanlimab
03
Conditions
melanomasquamous cell carcinoma of the head and neck (HNSCC)ovarian cancersarcomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02573259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02573259.